Skip to main content

Table 1 Demographic data for 185 patients with type 2 diabetes

From: The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus

Variable Descriptive statistics
Mean Median Minimum Maximum Std. dev.
Age (years) 67.11 67.00 43.00 85.00 8.01
BW (kg) at baseline 84.13 83.00 54.00 128.00 13.94
BW after 52 weeks (kg) 83.78 83.00 55.00 120.00 13.32
BMI (kg/m2) at baseline 30.37 30.04 20.66 52.60 4.58
BMI after 52 weeks (kg/m2) 30.23 29.76 22.55 47.26 4.31
HBA1c (%) at baseline 8.58 8.50 6.20 12.80 1.02
HBA1c after 52 weeks (%) 7.78 7.70 5.10 11.90 1.11
Fasting glucose levels at baseline (mmol/L) 11.74 11.30 5.20 21.30 2.81
Fasting glucose levels after 52 weeks (mmol/L) 8.73 8.20 4.40 17.70 2.37
Detemir dose (units/day) 34.39 32.00 5.00 120.00 14.84
T2DM duration (years) 16.15 16.00 3.00 38.00 5.95
Premix dose (IU/day) 60.51 56.00 22.00 180.00 22.44
Detemir dose per kg (units/kg/day) 0.41 0.38 0.08 1.30 0.16
  1. BW body weight, BMI body mass index